{
    "relation": [
        [
            "",
            "Number of Participants Analyzed [units: participants]",
            "Change From Baseline in Norfolk Quality of Life \u2013 Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6, Month 12 [units: units on a scale] Mean (Standard Deviation)",
            "Physical (P)functioning/large fiber:Baseline(n=21)",
            "P functioning/large fiber: Change at Month 6(n=19)",
            "P functioning/large fiber:Change at Month 12(n=18)",
            "ADLs: Baseline (n=21)",
            "ADLs: Change at Month 6 (n=19)",
            "ADLs: Change at Month 12 (n=18)",
            "Symptoms: Baseline (n=21)",
            "Symptoms: Change at Month 6 (n=19)",
            "Symptoms: Change at Month 12 (n=18)",
            "Small fiber neuropathy (SFN): Baseline (n=21)",
            "SFN: Change at Month 6 (n=19)",
            "SFN: Change at Month 12 (n=18)",
            "Autonomic neuropathy (AN): Baseline (n=21))",
            "AN: Change at Month 6 (n=19)",
            "AN: Change at Month 12 (n=18)"
        ],
        [
            "Tafamidis",
            "21",
            "",
            "25.60 (18.50)",
            "-2.60 (8.66)",
            "-1.40 (11.71)",
            "7.30 (7.01)",
            "0.10 (3.07)",
            "0.90 (2.58)",
            "9.00 (7.50)",
            "-0.90 (3.05)",
            "-0.10 (4.28)",
            "3.90 (4.92)",
            "-0.30 (2.54)",
            "0.70 (3.22)",
            "2.00 (1.96)",
            "-0.50 (1.61)",
            "-0.10 (1.13)"
        ]
    ],
    "pageTitle": "The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00630864?sect=Xj015&view=results",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988860.88/warc/CC-MAIN-20150728002308-00217-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 868006527,
    "recordOffset": 867995300,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Period 1: \u00a0 Part 1 (up to Week 6) Participant Flow for 2 periods Participants with transthyretin (TTR) variants other than valine replaced by methionine at position 30 (V30M) received tafamidis (Fx-1006A) 20 milligram (mg) capsule orally once daily up to Week 6 in Part 1, participants who achieved TTR stabilization at Week 6 or as per investigator\u2019s discretion continued to receive tafamidis (Fx-1006A) 20 mg capsule orally once daily up to Month 12 in Part 2. Tafamidis Description \u00a0 Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow",
    "textAfterTable": "Reporting Groups \u00a0 Description Tafamidis Participants with transthyretin (TTR) variants other than valine replaced by methionine at position 30 (V30M) received tafamidis (Fx-1006A) 20 milligram (mg) capsule orally once daily up to Week 6 in Part 1, participants who achieved TTR stabilization at Week 6 or as per investigator\u2019s discretion continued to receive tafamidis (Fx-1006A) 20 mg capsule orally once daily up to Month 12 in Part 2. Baseline Measures \u00a0 \u00a0 Tafamidis \u00a0 Number of Participants \u00a0 [units:\u00a0participants] \u00a0 21 \u00a0 Age \u00a0 [units:\u00a0years] Mean (Standard Deviation) \u00a0 63.10 \u00a0(9.86) \u00a0 Gender \u00a0 [units:\u00a0participants] \u00a0 Female \u00a0 \u00a0 8 \u00a0 Male \u00a0 \u00a0 13 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}